Usefulness of <scp>CD</scp>200 in the differential diagnosis of <scp>SDRPL</scp>,<scp> SMZL</scp>, and <scp>HCL</scp>

Favre, R.; Manzoni, Delphine; Traverse-Gléhen, Alexandra; Verney, Aurélie; Jallades, Laurent; Callet‐Bauchu, Evelyne; Sujobert, Pierre; Salles, Gilles; Baseggio, Lucile

doi:10.1111/ijlh.12824

Cited by 24 publications

(25 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A scoring system based on CD11c, CD22, CD76, CD38 and CD27 expression was designed to differentiate SDRPL from SMZL . In addition, CD200/CD180 median fluorescence (MFI) ratio may be helpful in distinguishing HCL from SDRPL, with a ratio of 0.5 or less in favor of SDRPL …”

Section: How Has the Diagnosis Of Hairy Cell Leukemia And Hcl‐like DImentioning

confidence: 99%

Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment

2019

View full text Add to dashboard Cite

Disease overview: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B-cell disorders. They are characterized by the identification of hairy cells, a specific genetic profile, a different clinical course and the need for appropriate treatment. Diagnosis: Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of three or four based on the CD11C, CD103, CD123, and CD25 expression. Also, the trephine biopsy which makes it possible to specify the degree of tumoral medullary infiltration and the presence of BRAF V600E somatic mutation. Risk stratification: Progression of patients with HCL is based on a large splenomegaly, leukocytosis, a high number of hairy cells in the peripheral blood and the immunoglobulin heavy chain variable region gene mutational status. The VH4-34 positive HCL cases are associated with poor prognosis. Treatment: Risk adapted therapy with purine nucleoside analogs (PNA) are indicated in symptomatic first line HCL patients. The use of PNA followed by rituximab represents an alternative option. Management of progressive or refractory disease is based on the use of BRAF inhibitors associated or not with MEK inhibitors, recombinant immunoconjugates targeting CD22 or BCR inhibitors.

show abstract

Section: How Has the Diagnosis Of Hairy Cell Leukemia And Hcl‐like DImentioning

confidence: 99%

Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment

2019

View full text Add to dashboard Cite

show abstract

“…The disease affects the elderly population without predominance based on sex. The median age of the patients was higher than that observed in HCL, as 71 years (48-92) (18). HCL-V cases are typically characterized by splenomegaly and a high lymphocyte count without neutropenia or monocytopenia.…”

Section: Hcl-like Disordersmentioning

confidence: 82%

Epidemiology of Hairy Cell Leukemia (HCL) and HCL-Like Disorders

Troussard

2020

MRAJ

View full text Add to dashboard Cite

Hairy cell leukemia (HCL) is a very rare and well-defined entity that is characterized by the presence of hairy cells expressing the characteristic markers CD11c, CD25, CD103 and CD123 and in most cases by the presence of the BRAFV600E mutation. The incidence rate, directly adjusted to the 2000 United States standard population is estimated at 0.62 per 100 000 person-years (PA) in white men, 0.21 in black men, 0.20 in Asian men and 0.06 American Indian or Alaska native men. Based on the estimated 2019 leukemia incidence, of 61,780 in the United States, approximately 1,240 new HCL cases are expected per year, with only 60–75 new patients having a variant form of HCL each year. In France, the median age of patients at diagnosis is 63 years in men and 59 years in women. There is a strong male predominance, with a sex ratio of 5:1. HCL is a malignant disorder with a good prognosis, with a standardized average survival at 1 year and 5 years of 95% (95% CI: 91-97 for both). The etiology of HCL remains unknown. The risk of secondary cancers is high, especially that of another malignant hematologic disorder. This high risk justifies the need for prolonged hematological monitoring. HCL must be distinguished from other HCL-like disorders, including the variant form of HCL (HCL-V) or splenic diffuse red pulp lymphoma (SDRPL), warranting the development of international epidemiologic studies.

show abstract

“…In these cases, chronic lymphocytic leukemia (CLL) should be excluded. CD200 expression constitutes a major immunological marker in the differential diagnosis of CD5+ small B-cell lymphomas; for example, mantle cell lymphoma is CD200-negative (in contrast to SMZL) and also in small B-cell lymphomas with villous cytoplasm; SDRPL is dimly CD200-positive, whereas HCL is strongly CD200-positive [ 25 ]. Proliferative index using Ki67/Mib1 is generally low, with a characteristical pattern (high in the germinal center and the marginal zone and low elsewhere) [ 6 ].…”

Section: Resultsmentioning

confidence: 99%

“…Oncol. 2021, 28 (in contrast to SMZL) and also in small B-cell lymphomas with villous cytoplasm; SD is dimly CD200-positive, whereas HCL is strongly CD200-positive [25]. Proliferative in using Ki67/Mib1 is generally low, with a characteristical pattern (high in the germ center and the marginal zone and low elsewhere) [6].…”

Section: Cytology Immunophenotype and Pathologymentioning

confidence: 99%

New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas

et al. 2021

View full text Add to dashboard Cite

Splenic marginal zone lymphoma (SMZL) is a small B-cell lymphoma, which has been recognized as a distinct pathological entity since the WHO 2008 classification. It classically presents an indolent evolution, but a third of patients progress rapidly and require aggressive treatments, such as immuno-chemotherapy or splenectomy, with all associated side effects. In recent years, advances in the comprehension of SMZL physiopathology have multiplied, thanks to the arrival of new devices in the panel of available molecular biology techniques, allowing the discovery of new molecular findings. In the era of targeted therapies, an update of current knowledge is needed to guide future researches, such as those on epigenetic modifications or the microenvironment of these lymphomas.

show abstract

Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL

Cited by 24 publications

References 11 publications

Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment

Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment

Epidemiology of Hairy Cell Leukemia (HCL) and HCL-Like Disorders

New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas

Contact Info

Product

Resources

About